Growth Hormone Deficiency Market Report 2026

The growth hormone deficiency market size has grown strongly in recent years. It will grow from $4.3 billion in 2025 to $4.55 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to improved diagnostic capabilities for pituitary disorders, increased awareness of growth hormone deficiency, expansion of pediatric endocrinology services, availability of recombinant hormone treatments, improved healthcare access.

The growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $5.67 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing demand for personalized hormone therapies, rising investments in endocrine research, expansion of home-based treatment administration, growing use of digital health monitoring tools, increasing focus on long-acting growth hormone formulations. Major trends in the forecast period include increasing adoption of recombinant growth hormone therapies, rising use of personalized treatment approaches, growing focus on early diagnosis of hormonal disorders, expansion of long-term hormone replacement programs, enhanced monitoring of treatment outcomes.

The increasing prevalence of genetic disorders is expected to drive the growth of the growth hormone deficiency market in the coming years. Genetic disorders are medical conditions caused by abnormalities or mutations in an individual’s DNA, which may be inherited or arise spontaneously. The rising prevalence of these disorders is attributed to advances in diagnostic technologies, greater awareness, increasing maternal age, environmental factors that induce mutations, population growth, and improved survival rates among affected individuals. Growth hormone deficiency therapies are used to manage growth-related complications associated with certain genetic conditions. For example, in October 2024, according to the Cystic Fibrosis Trust, a UK-based charity supporting individuals with cystic fibrosis, approximately 11,148 cystic fibrosis patients were registered in 2022, increasing to 11,318 in 2023, representing a 1.5% year-over-year rise. Therefore, the growing prevalence of genetic disorders is driving the growth of the growth hormone deficiency market.

Major companies operating in the growth hormone deficiency market are concentrating on the development of innovative products, such as unmodified somatropin formulations, to improve pediatric growth hormone deficiency treatment. Unmodified somatropin refers to the same growth hormone traditionally used in daily pediatric therapies but delivered through a once-weekly dosing regimen, as seen with newer products. For instance, in September 2023, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched SKYTROFA (lonapegsomatropin) for the once-weekly treatment of pediatric growth hormone deficiency. This therapy provides greater convenience, supports improved patient adherence, and may deliver better treatment outcomes compared with conventional daily growth hormone injections. It is the first and only FDA-approved once-weekly therapy for pediatric GHD, representing a significant advancement in endocrinology and pediatric treatment.

In October 2024, Double Point Ventures LLC (DPV), a US-based investment firm, acquired Lumos Pharma for an undisclosed amount. Through this acquisition, DPV aims to advance the development and potential commercialization of Lumos Pharma’s oral growth hormone secretagogue for pediatric growth hormone deficiency, while also strengthening its position in the rare endocrine disorders market. Lumos Pharma is a US-based clinical-stage biopharmaceutical company focused on developing treatments for pediatric growth hormone deficiency.

Major companies operating in the growth hormone deficiency market are Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck KGaA, Ipsen, Ascendis Pharma A/S, Opko Health Inc., Genentech Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Ferring Pharmaceuticals, JCR Pharmaceuticals, LG Chem, BioPartners, GeneScience Pharmaceuticals, SciClone Pharmaceuticals, AnkeBio, Versartis, Aeterna Zentaris.

North America was the largest region in the growth hormone deficiency market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the growth hormone deficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the growth hormone deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the growth hormone deficiency market by increasing costs of imported active pharmaceutical ingredients, bioprocessing equipment, cold-chain logistics systems, and injection delivery devices. Pharmaceutical manufacturing and hospital procurement in North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces pricing pressure on imported therapies. These tariffs are increasing treatment costs and reimbursement challenges. At the same time, they are encouraging domestic biologics manufacturing, local formulation development, and regional supply chain strengthening for hormone therapies.

The growth hormone deficiency market research report is one of a series of new reports that provides growth hormone deficiency market statistics, including growth hormone deficiency industry global market size, regional shares, competitors with a growth hormone deficiency market share, detailed growth hormone deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the growth hormone deficiency industry. This growth hormone deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Growth hormone deficiency (GHD) is a medical condition in which the pituitary gland fails to produce sufficient levels of growth hormone (GH). This insufficiency results in impaired growth and development in children and various metabolic abnormalities in adults. Growth hormone deficiency may be congenital, meaning present at birth, or acquired due to factors such as injury, tumors, infections, or other conditions affecting the pituitary gland.

The main types of growth hormone deficiency include pediatric growth hormone deficiency and adult growth hormone deficiency. Pediatric growth hormone deficiency affects children with inadequate growth hormone secretion, leading to reduced growth and delayed physical development. Treatment options include pharmacological therapy, recombinant human growth hormone, human pituitary gland extracts, and surgery. These treatments are administered through routes such as intravenous, intramuscular, and others, and are distributed via hospital pharmacies, online pharmacies, and retail pharmacies. They are used by various end users, including hospitals, home care settings, specialty clinics, and others.

The growth hormone deficiency market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and specialized services. The market value includes the value of related goods sold by the service provider or included within the service offering. The growth hormone deficiency market consists of sales of recombinant human growth hormones, long-acting growth hormones and combination therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.